Nuvation Bio's Ibtrozi Gains FDA Nod to Compete in Lung Cancer MarketFDANuvation Bio’s Ibtrozi (taletrectinib) secures FDA approval for treating ROS1-positive non-small cell lung cancer, offering a next-gen alternative to Pfizer, BMS, and Roche therapies with strong efficacy and CNS safety.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
